These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29976041)

  • 1. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
    Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
    Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.
    Ahn GY; Suh CH; Kim YG; Park YB; Shim SC; Lee SH; Lee SS; Bae SC; Yoo DH
    J Korean Med Sci; 2020 Sep; 35(38):e335. PubMed ID: 32989931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort.
    Gamba A; Depascale R; Zanatta E; Ienna L; Cruciani C; Gatto M; Zen M; Doria A; Iaccarino L
    Clin Rheumatol; 2024 Oct; 43(10):3167-3174. PubMed ID: 39196499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
    de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
    Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
    Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
    J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
    Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
    Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.
    Nalotto L; Iaccarino L; Zen M; Gatto M; Borella E; Domenighetti M; Punzi L; Doria A
    Immunol Res; 2013 Jul; 56(2-3):362-70. PubMed ID: 23572427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose rituximab is efficacious in refractory idiopathic inflammatory myopathies.
    Janardana R; Amin SN; Rajasekhar L; Pinto B; Kodishala C; Selvam S; Shobha V
    Rheumatology (Oxford); 2023 Mar; 62(3):1243-1247. PubMed ID: 35946502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.
    Muñoz-Beamud F; Isenberg DA
    Clin Exp Rheumatol; 2013; 31(6):896-903. PubMed ID: 24050676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
    Leclair V; Galindo-Feria AS; Dastmalchi M; Holmqvist M; Lundberg IE
    Rheumatology (Oxford); 2019 Jul; 58(7):1214-1220. PubMed ID: 30690633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
    Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
    Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
    Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
    J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature.
    Sanges S; Yelnik CM; Sitbon O; Benveniste O; Mariampillai K; Phillips-Houlbracq M; Pison C; Deligny C; Inamo J; Cottin V; Mouthon L; Launay D; Lambert M; Hatron PY; Rottat L; Humbert M; Hachulla E
    Medicine (Baltimore); 2016 Sep; 95(39):e4911. PubMed ID: 27684828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].
    Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z
    Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
    Manwatkar A; Naresh K; Mathew J; Nair AV; Goel R; Yadav B; Prakash JAJ; Das JK; Sivadasan A
    Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38814804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: a retrospective observational study.
    Bae S; Charles-Schoeman C
    Clin Rheumatol; 2018 Aug; 37(8):2113-2123. PubMed ID: 29971584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
    Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
    Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.